Levocarnitine

Generic Name: Levocarnitine

Brand Names: Carnitor

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅NO_₃

CAS Number: 541-15-1

Unique Ingredient Identifier: 0G389FZZ9M

Background: Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

Indication: ⑴用于继发性肉碱缺乏症。主要用于慢性肾衰长期血透患者因肉碱缺乏产生的一系列并发症状，临床表现如心肌病、骨骼肌病、心律失常、高脂血症，以及低血压和透析中肌痉挛等。

⑵用于罕见病β-酮硫解酶缺乏症（BKD）和原发性肉碱缺乏症（PCD）。

⑶用于罕见病戊二酸Ⅰ型。

⑷用于维持罕见病同型半胱氨酸血症引起的血液游离肉碱的正常水平。

Associated Conditions: Carnitine Deficiency, Congenital carnitine deficiency, Secondary Carnitine deficiency

Associated Therapies: -

Clinical Trials

L-Carnitine in Peritoneal Dialysis

Phase 2

Completed

Conditions: End-Stage Renal Disease

Interventions: Drug: L-carnitine

First Posted Date: 2009-06-17

Last Posted Date: 2010-02-23

Lead Sponsor: Iperboreal Pharma Srl

Target Recruit Count: 4

Registration Number: NCT00922701

Locations: 🇮🇹
Division of Nephrology, University of "G. d'Annunzio", Chieti, Italy

L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis

Phase 2

Completed

Conditions: End-Stage Renal Disease

Interventions: Drug: L-Carnitine

First Posted Date: 2009-02-26

Last Posted Date: 2019-06-25

Lead Sponsor: Iperboreal Pharma Srl

Target Recruit Count: 5

Registration Number: NCT00851838

Locations: 🇮🇹
Division of Nephrology, University of "G. d'Annunzio", Chieti, Italy

Early Administration of L-carnitine in Hemodialysis Patients

Phase 3

Completed

Conditions: Hyperthyroidism Treated or Under Control
Complication of Hemodialysis

Interventions: Drug: L-Carnitine

First Posted Date: 2006-05-05

Last Posted Date: 2011-05-04

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 110

Registration Number: NCT00322322

Locations: 🇫🇷
HOPITAL LA PITIE SALPETRIERE, service de Néphrologie, Paris, France
🇫🇷
Assistance Publique Hopitaux de Paris, Paris, France

Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Phase 2

Terminated

Conditions: Heart Failure

First Posted Date: 2005-11-02

Last Posted Date: 2022-08-16

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 36

Registration Number: NCT00247975

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

L-Carnitine to Treat Fatigue in AIDS Patients

Phase 2

Completed

Conditions: HIV Infections
AIDS

Interventions: Other: Placebo
Drug: L-carnitine

First Posted Date: 2004-03-10

Last Posted Date: 2008-09-04

Lead Sponsor: National Institute of Nursing Research (NINR)

Target Recruit Count: 44

Registration Number: NCT00079599

Locations: 🇺🇸
Department of Pain Medicine and Palliative Care; Beth Israel Medical Center; First Avenue at 16th Street, New York, New York, United States

Developmental Study on Fatigue in Cancer

Phase 2

Completed

Conditions: Neoplasms

First Posted Date: 2002-04-30

Last Posted Date: 2006-08-18

Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Target Recruit Count: 140

Registration Number: NCT00034450

Locations: 🇺🇸
Beth Israel Medical Center, New York, New York, United States

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 440

Registration Number: NCT00000885

Locations: 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸
Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸
Boston Med Ctr, Boston, Massachusetts, United States

and more 50 locations

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 120

Registration Number: NCT00002184

Locations: 🇺🇸
Krauss Med Partners / Dept of Research and Development, Los Angeles, California, United States
🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇵🇷
Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico

and more 12 locations

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 100

Registration Number: NCT00002379

Locations: 🇺🇸
Phoenix Body Positive, Phoenix, Arizona, United States
🇺🇸
Saint Vincent's AIDS Ctr, New York, New York, United States
🇺🇸
George Washington Med Ctr, Washington, District of Columbia, United States

and more 12 locations

Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children

Phase 2

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 36

Registration Number: NCT00002219

Locations: 🇺🇸
Bronx Lebanon Hosp Ctr / Dept of Pediatrics, Bronx, New York, United States
🇺🇸
St Lukes Roosevelt Hosp Ctr, New York, New York, United States
🇺🇸
Tulane Univ Med Ctr / Dept of Pediatrics, New Orleans, Louisiana, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy